Clinical Trials Logo

Clinical Trial Summary

Since its initial description in December 2019 in Wuhan , China, Corona virus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), has rapidly evolved into a worldwide pandemic affecting millions of lives . Unlike adults, the vast majority of children with COVID-19 have mild symptoms. However, there are children who have significant respiratory disease, and some children may develop a hyper inflammatory response similar to what has been observed in adults with COVID-19. Furthermore, in late April 2020, reports emerged of children with a different clinical syndrome resembling Kawasaki disease (KD) and toxic shock syndrome; these patients frequently had evidence of prior exposure to SARS-CoV-2. The pathophysiology of MIS-C: Is unclear ,but it appears to be a consequence of a exacerbated immune system response or maladaptive response of the host .After the virus enters the human cells, the first line of defense against infection should be a quick and well-coordinated immune response ;however, when this mechanism is unregulated and excessive ,hyper inflammation can occur. Cytokines that play an important role in inducing immunity and immunopathology during infections in excess can cause the clinical syndrome known as cytokine storm. The inflammatory response caused by SARS-CoV-2appears to be the major cause of mortality in infected patients . The infection of dendritic cells or macrophages by SARS-CoV-2 induces the production of low levels of antiviral cytokines and increases the production of inflammatory cytokines (tumor necrosis factor[TNF], interleukin[IL]-1, IL-6,and interferon ).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Multisystem Inflammatory Syndrome in Children
  • Syndrome

NCT number NCT05382234
Study type Observational
Source Sohag University
Contact Youstina R Attia, residant
Phone 01275866826
Email youstinarashed@med.sohag.edu.eg
Status Not yet recruiting
Phase
Start date June 1, 2022
Completion date June 1, 2023

See also
  Status Clinical Trial Phase
Terminated NCT05022303 - AT1001 for the Treatment of COVID-19 Related MIS-C Phase 2
Completed NCT04347408 - Seroprevalence of SARS-Cov-2 Antibodies in Children
Withdrawn NCT04549285 - Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome Phase 1
Recruiting NCT05186597 - Incidence of MIS-C and Other Complications Following SARS-CoV-2 Infection
Recruiting NCT05582512 - Clinical Characteristics and Long Term Impact on Pediatric COVID-19 in Taiwan
Recruiting NCT05334134 - COVID-19: Immunological Mechanisms in Multisystem Inflammatory Syndrome in Children
Recruiting NCT04844242 - MISC COVID-19 Study in Pediatric Population
Recruiting NCT05576714 - Investigation of Prognostic Biomarkers, Host Factors and Viral Factors for COVID-19 in Children